Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879 | 0.83 | PDPK1 (0.44) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL2094594 | 0.82 | PYCR1 (0.46) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL31448605 | 0.79 | PYCR1 (0.47) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL20465750 | 0.79 | PYCR1 (0.47) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL308050 | 0.79 | PYCR1 (0.47) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL29393338 | 0.79 | PYCR1 (0.47) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL15806743 | 0.79 | PYCR1 (0.47) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL15654337 | 0.78 | CYP2A6 (0.35) | PYCR1HSP90AA1 | |
| SCHEMBL20465747 | 0.77 | PYCR1 (0.46) | PYCR1KDM1AAKR1B1PDPK1DGAT1 | |
| SCHEMBL12069853 | 0.77 | PYCR1 (0.46) | PYCR1KDM1AAKR1B1PDPK1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112340-B1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO, AND PRECURSOR OF 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO | STELLA PHARMA CORP (JP) | 2020-07-15 | — | — | EP | claimed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-1460110-A1 | New halogeno-aromatic substituted indolestyryl dyes for optical data recording media | CLARIANT INTERNATIONAL LTD. (CH) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PYCR1 4393/4885KDM1A 1196/4885AKR1B1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.